Skip to main content

RNAi / siRNA Deal Benchmarks in Hematology

Median Upfront
$695M
Range: $364M - $1.0B
Total Deal Value
$3.4B
Range: $2.1B - $4.7B
Royalty Rate
8.9% - 16.7%
Tiered up to 20.7%
Dev Milestones
$574M
Range: $370M - $780M
Model Your Deal

Market Analysis

RNAi / siRNA therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in hematology is $695M, with total deal values reaching $3.4B. Development milestones average $574M, while regulatory milestones contribute $684M.

The hematology rnai / sirna landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna hematology deals range from 8.9% to 16.7% at the base tier, with tiered escalation reaching 12.9%-20.7% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna hematology licensing deal?
Based on our analysis, Phase 2 rnai / sirna licensing deals in hematology average $695M in upfront payments, with a range of $364M to $1.0B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for rnai / sirna hematology transactions?
The median total deal value for Phase 2 rnai / sirna assets in hematology is $3.4B, ranging from $2.1B to $4.7B. This includes development milestones ($574M), regulatory milestones ($684M), and commercial milestones ($1.5B).
What royalty rates are standard for rnai / sirna deals in hematology?
Base royalty rates for rnai / sirna hematology transactions range from 8.9% to 16.7%, with tiered escalations reaching 12.9%-20.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in rnai / sirna hematology deals?
RNAi / siRNA hematology deals allocate approximately 80% of total deal value to milestones. Development milestones ($574M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($684M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

CAR-T (Hematologic) in Hematology

View

Bispecific Antibody in Hematology

View

RNAi / siRNA in Oncology

View

RNAi / siRNA in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included